- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01367782
A Double Blind Sham-controled Study to Evaluate the Influence of Low Frequency Repetitive Transcranial Stimulation (r-TMS) on Motor and Cognitive Measurements in Patients With Asymmetric Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PD patients with asymmetric disease aged 40 years or older, diagnosed as idiopathic PD according to the UK Brain Bank criteria, with Hoehn & Yahr stages II - IV while "off" will be recruited. Participants on antidepressants should be at least 2 months on stable therapy.
Patient will be excluded if:
- Patients who have concomitant epilepsy, a history of seizure or heat convulsion or history of epilepsy in first degree relative.
- Patients on neuroleptics.
- Patients with unstable medical disorder.
- History or current unstable hypertension.
- History of head injury or neurosurgical interventions.
- History of any metal in the head (outside the mouth).
- Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
- History of migraine or frequent or severe headaches.
- Current hearing loss.
- The presence of cochlear implants
- Current drug abuse or alcoholism.
- Pregnancy or not using a reliable method of birth control.
- Participation in current clinical study or clinical study within 30 days prior to this study.
Patients will be to randomized to an active rTMS arm or to a sham stimulation arm. Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes). The control arm group will receive sham stimulations in identical treatment and maintenance schedules. Patients from the sham group who will complete the study will be given the opportunity to receive 12 sessions of real r-TMS treatment over 4 weeks as the treatment group.
The following outcome measures will be taken prior to the treatment (screening visit), and at day 1, 10, 30, 60 and 90. Evaluation will be while subjects are both at "on" and "off".
Motor:
- Unified Parkinson's Disease Rating Scale (UPDRS )
- Clinical Global Impression of Severity (CGIS)
- Pegboard test.
- Tapping test
- Up & Go test
- Abnormal Involuntary Movement Scale (AIMS) Mood and affect
1. Beck Depression Inventory (BDI) Cognition
- Mini mental State examination (MMSE)
- Digit forward and backward tests.
- Word fluency.
- Frontal Assessment Battery (FAB)
Side effects will be closely monitored by the researchers and will be promptly reported to the IRB.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Oren Cohen, MD
- Phone Number: +972-3-5305296
- Email: Oren.Cohen@sheba.health.gov.il
Study Locations
-
-
-
Tel Hashomer, Israel, 52621
- Recruiting
- Sheba Medical Center
-
Contact:
- Oren Cohen, MD
- Email: Oren.Cohen@sheba.health.gov.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- PD patients with asymmetric disease aged 40 years or older, diagnosed as idiopathic PD according to the UK Brain Bank criteria, with Hoehn & Yahr stages II - IV while "off".
- Participants on antidepressants should be at least 2 months on stable therapy.
Exclusion Criteria:
- Patients who have concomitant epilepsy, a history of seizure or heat convulsion or history of epilepsy in first degree relative.
- Patients on neuroleptics.
- Patients with unstable medical disorder.
- History or current unstable hypertension.
- History of head injury or neurosurgical interventions.
- History of any metal in the head (outside the mouth).
- Known history of any metallic particles in the eye, implanted cardiac pacemaker, implanted neurostimulators, surgical clips (above the shoulder line) or any medical pumps.
- History of migraine or frequent or severe headaches.
- Current hearing loss.
- The presence of cochlear implants
- Current drug abuse or alcoholism.
- Pregnancy or not using a reliable method of birth control.
- Participation in current clinical study or clinical study within 30 days prior to this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active repetitive Transcranial Stimulation
Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
|
Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
|
Sham Comparator: Sham Stimulation
The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
|
Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decrease in Unified Parkinson's Disease Rating Scale (UPDRS) score
Time Frame: 3 months
|
A decrease in the total UPDRS score in general and in the Motor UPDRS (part 3) score.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGIS
Time Frame: 3 months
|
Rater and patient's opinion on the change in thier PD due to the TMS treatment
|
3 months
|
Decrease in time in Pegboard test
Time Frame: 3 months
|
3 months
|
|
Increase in Tapping test
Time Frame: 3 months
|
3 months
|
|
Decrease in Time Up&Go test
Time Frame: 3 months
|
Patient has to get up from a chair, walk 3 meters, turn around and return to sit on the chair.
|
3 months
|
Increase in Word fluency
Time Frame: 3 months
|
Number of words the patient can think of that start with a certian letter or belong to a certian catagory, in one minute.
|
3 months
|
Increase in Digits Forward & Backwards test
Time Frame: 3 months
|
3 months
|
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Oren Cohen, MD, Sheba Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHEBA-11-8470-OC-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asymmetric Parkinson's Disease
-
Shahid Beheshti University of Medical SciencesUnknownAsymmetric Dissociated Vertical DeviationIran, Islamic Republic of
-
Tel-Aviv Sourasky Medical CenterWolfson Medical CenterCompletedObesity | Diabetes Mellitus, Type 2 | Arginine | Asymmetric DimethylarginineIsrael
-
Sahmyook UniversityCompletedPostoperative Pain | Shoulder Injuries | Immobilization | Muscle Disorder | Asymmetric Limb Muscle StiffnessKorea, Republic of
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Washington University School of MedicineChildren's Hospital of Philadelphia; University of Southern California; University... and other collaboratorsRecruitingUnilateral Deafness | Asymmetric Hearing Loss | Single-sided DeafnessUnited States
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
Hadassah Medical OrganizationUnknownComplex Regional Pain Syndrome | Arthroscopic Knee Surgery | Lower Limb Fractures | Back Pain and Asymmetric Gait
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
Clinical Trials on repetitive transcranial stimulation (r-TMS)
-
Sheba Medical CenterWeizmann Institute of ScienceCompletedParkinson's DiseaseIsrael
-
University of FloridaActive, not recruiting
-
Northwestern UniversityNeuroneticsCompletedDepression | Anxiety | Cancer in Remission (Any Type or Stage)United States
-
VA Office of Research and DevelopmentUniversity of California, Los Angeles; Minneapolis Veterans Affairs Medical... and other collaboratorsRecruiting
-
Stanford UniversityMedical University of South Carolina; University of South Florida; Minneapolis... and other collaboratorsRecruiting
-
Centre hospitalier de Ville-Evrard, FranceUnknownMajor Depressive DisorderFrance
-
University of California, San FranciscoRecruiting
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Yale UniversityNational Institute of Mental Health (NIMH)TerminatedSchizophrenia | Schizo Affective Disorder | Auditory HallucinationUnited States